Represents the term of the collaborative arrangement.

No definition available.

Name:	cldx_CollaborativeArrangementAgreementTerm
Namespace Prefix:	cldx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the percentage of interest in net royalties sold.

+ References

No definition available.

+ Details

Name:	cldx_PercentageOfInterestInNetRoyaltiesSold
Namespace Prefix:	cldx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of license fee payable to third party on net royalties received.

+ References

No definition available.

+ Details

Name:	cldx_PercentageOfLicenseFeeDueOnNetRoyaltiesReceived
Namespace Prefix:	cldx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents percentage of reimbursement of external costs incurred by the company.

+ References

No definition available.

+ Details

Name:	cldx_ReimbursementOfExternalCostsIncurredPercentage
Namespace Prefix:	cldx_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

This element represents revenue earned during the period arising from products sold or services provided under the terms of a contract. Also include revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.

+ References

No definition available.

+ Details

Name:	cldx_RevenueFromContractsAndGrants
Namespace Prefix:	cldx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

This element represents revenue from product development and licensing agreements.

+ References

No definition available.

+ Details

Name:	cldx_RevenueFromProductDevelopmentAndLicensingAgreements
Namespace Prefix:	cldx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)
-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.3)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=cldx_BristolMeyersSquibbCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cldx_Pd1ImmuneCheckpointInhibitorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cldx_RockefellerUniversityMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cldx_CollaborativeArrangementForDevelopmentAndCommercializationOfProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cldx_GlaxoSmithKlinePlcMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=cldx_RotarixRotavirusVaccineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cldx_LicenseAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cldx_CincinnatiChildrensHospitalMedicalCenterMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=cldx_RoyaltyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=cldx_PRFAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

REVENUE (Details) - USD ($) $ in Thousands	1 Months Ended			12 Months Ended
REVENUE (Details) - USD ($) $ in Thousands	May. 31, 2014	May. 31, 2005	May. 31, 1995	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
REVENUE
Deferred Revenue				$ 4,368	$ 5,297
Product development and licensing agreements revenue				1,442	838	$ 160
Contracts and grants revenue				4,038	2,748	1,617
Product royalty expense						2,334
BMS \| PD-1 Immune Checkpoint Inhibitor
REVENUE
Deferred Revenue	$ 5,000
Term of the agreement	5 years
Reimbursement of external costs incurred by the company (as a percent)	50.00%
Product development and licensing agreements revenue				1,300	700
Rockefeller
REVENUE
Contracts and grants revenue				$ 3,400	$ 2,700	1,400
Collaboration arrangement for development and commercialization of oral rotavirus strain \| Glaxo \| Rotarix
REVENUE
Product royalty expense						$ 2,300
License agreements \| Cincinnati Children's Hospital Medical Center \| Rotarix
REVENUE
Percentage of license fee payable on net royalties received			30.00%
Royalty Agreement \| PRF \| Rotarix
REVENUE
Percentage of interest in net royalties sold		70.00%